Eris Lifesciences Limited has announced the appointment of Mr. Vineet Varma as Additional Director (Non-Executive, Independent) effective March 14, 2026. The pharmaceutical company informed stock exchanges about this strategic board appointment through a regulatory filing under SEBI Listing Regulations.

Board Appointment Details

The Board of Directors approved Mr. Varma's appointment based on the recommendation of the Nomination and Remuneration Committee through a Circular Resolution dated March 14, 2026. The appointment carries specific terms and regulatory compliance requirements.

Professional Background and Expertise

Mr. Vineet Varma brings extensive experience to Eris Lifesciences' board, with a distinguished career spanning over two decades in the banking sector. His professional credentials demonstrate deep expertise in multiple areas of financial services and institutional banking.

Key areas of his expertise include:

• Transaction banking and trade management
• Cash management and supply chain financing
• Global markets and treasury operations
• Corporate banking services

Mr. Varma has played instrumental roles in building financial institutions businesses at prominent banks including FAB, NBAD, and ABN Amro Banks. His experience extends to advisory roles, having served as Client Advisory Board Member at Citibank and Bank of America Merrill Lynch.

Educational Qualifications

Mr. Varma's educational background includes prestigious institutions that have shaped his professional expertise. He is an alumnus of London Business School and Shriram College of Commerce, providing him with a strong foundation in business management and commerce.

Regulatory Compliance and Independence

The company has confirmed that Mr. Varma meets all regulatory requirements for the independent director position. According to the disclosure, he is not debarred from holding the office of Director by SEBI or any other regulatory authority. Additionally, Mr. Varma is not related to any existing Director of the Company, ensuring his independence as per corporate governance norms.

Corporate Governance Enhancement

This appointment reflects Eris Lifesciences' commitment to strengthening its board composition with experienced professionals from diverse industry backgrounds. The addition of Mr. Varma's banking and financial services expertise is expected to provide valuable insights for the pharmaceutical company's strategic decisions and growth initiatives. The appointment is subject to approval by the company's members and aligns with the company's corporate governance framework.

Eris Lifesciences Limited has announced its participation in an upcoming investor conference with Capital Group, scheduled for March 19, 2026. The announcement was made on March 13, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Meeting Details

The investor meeting is structured as follows:

Regulatory Compliance

The company has emphasized its commitment to regulatory compliance by making this announcement under SEBI's listing regulations. Eris Lifesciences has specifically noted that the schedule is indicative and subject to changes due to any unforeseen developments.

The company has also clarified its approach to information sharing during the meeting. Management will refer only to publicly available documents for discussions during the interaction, ensuring that no unpublished price sensitive information (UPSI) will be discussed during the meeting.

Company Leadership

The announcement was signed by Milind Talegaonkar, Company Secretary & Compliance Officer (Membership No: A26493), who digitally signed the document on March 13, 2026. The company maintains its registered and corporate office at Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054.

This investor meeting represents part of Eris Lifesciences' ongoing engagement with institutional investors and analysts as part of its investor relations activities.